Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety surveillance of artemether-lumefantrine and dihydroartemisinin-piperaquine for uncomplicated falciparum malaria in Bangladesh
ACTRN12623000239662Phase 4Not yet recruiting
- Sponsor
- Ministry of Health and Family Welfare
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artemether + lumefantrine, dihydroartemisinin + piperaquine and primaquine in Malaria (2 arms), sponsored by Ministry of Health and Family Welfare. Primary endpoints: Adequate clinical and parasitological response for artemether-lumefantrine, PCR differentiation of recrudescence versus new infection and 2 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
artemether + lumefantrinedihydroartemisinin + piperaquineprimaquine
03
Conditions
Malaria
Beyond the preview
Go deeper on ACTRN12623000239662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000239662.